Inés Harguindeguy

Inés Harguindeguy

Auto-generated profile, based on publicly available information

Inés Harguindeguy

Center for Research and Development of Industrial Fermentations (CINDEFI CONICET-UNLP), La Plata, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2025 in Biotechnology Journal
Verified
Journal Article
Closed access
IHInés Harguindeguy
Inés Harguindeguy
MAMatias Hernan Assandri
Matias Hernan Assandri
JGJuan P. Gorgojo
Juan P. Gorgojo
YHYanina Hiriart
Yanina Hiriart
VAVanina Alarcón
Vanina Alarcón
GOGastón E. Ortiz
Gastón E. Ortiz

22 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
IHInés Harguindeguy
Inés Harguindeguy
MAMatias Hernan Assandri
Matias Hernan Assandri
MMM. Antonieta Daza Millone
M. Antonieta Daza Millone
SCSebastián F Cavalitto
Sebastián F Cavalitto
MSMaria de los Angeles Serradell
Maria de los Angeles Serradell
GOGastón E. Ortiz
Gastón E. Ortiz
Immunocastration, a non-surgical strategy based on active immunization against gonadotropin-releasing hormone (GnRH), effectively suppresses steroidogenesis and spermatogenesis. However, peptide vaccines targeting poorly immunogenic antigens such as GnRH often fail to elicit robust adaptive immune responses, requiring adjuvants or carrier proteins. Previously, we introduced Coated Bacterial Vaccines (CBVs), a platform that uses chemically inactivated Gram-positive bacteria to display recombinant antigens fused to the SlpA carboxy-terminal domain (dSLPA) on their surface. This system leverages natural pathogen-associated molecular patterns (PAMPs) to enhance immunogenicity without additional adjuvants. In this work, we extended the application of the CBVs platform to enhance the immune response against a poorly immunogenic GnRH-based peptide vaccine. GnRH-CBVs were formulated using inactivated Bacillus subtilis var. natto coated with a recombinant GnRH tandem-repeat–dSLPA fusion protein and administered to male BALB/c mice. A chitosan-adjuvanted GnRH-dSLPA formulation served as a positive control. GnRH-CBVs induced a strong Th2-biased humoral response, characterized by predominant IgG1 levels comparable to those achieved with chitosan. The resulting antibodies effectively neutralized endogenous GnRH, reducing steroidogenesis and spermatogenesis and inducing marked testicular histological alterations. These findings support CBVs as a promising strategy to enhance peptide vaccine immunogenicity for veterinary immunocastration.

9 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAndrea Carolina Ramirez Gutierrez
Andrea Carolina Ramirez Gutierrez
IHInes Harguindeguy
Ines Harguindeguy
MHMelisa Samanta Homse
Melisa Samanta Homse
ASAlan Eric Sabetta
Alan Eric Sabetta
SCSebastian Fernando Cavalitto
Sebastian Fernando Cavalitto
GOGaston Ezequiel Ortiz
Gaston Ezequiel Ortiz
The purification of industrial enzymes typically relies on costly, multi-step chromatographic protocols. To address this, we developed a novel platform termed Coated Bacterial Enzymes (CBEs), which enables one-step purification and immobilization of recombinant proteins fused to the SlpA cell wall binding domain. As a proof of concept, we used a β-galactosidase from Bifidobacterium bifidum of dairy relevance. The chimeric enzyme BbgII-SlpA was expressed in Escherichia coli and captured from crude lysate onto glutaraldehyde-inactivated Bacillus subtilis cells via SlpA domain. Binding was characterized by a dissociation constant (Kd) of 16.2 µM and maximum binding capacity (Bmax) of 144 µmol/g. The resulting CBE biocatalyst exhibited optimal activity at pH 6.0 for ONPG and lactose, with a broader pH profile than the free enzyme. Optimal temperatures were 60 °C for ONPG and 50 °C for lactose, and CBE retained >80% activity after 390 min at 45 °C, compared to 20% for the free enzyme. Catalytic efficiencies (kcat/Km) were 2.62 ×10 6 M -1 ·s -1 for ONPG and 4.40 ×10 2 M -1 ·s -1 for lactose. Moreover, CBE showed improved tolerance to cations such as Ca 2+ and Fe 2+ . These results suggest that the CBE platform offers a cost-effective alternative for producing high-purity, immobilized enzymes for diverse industrial bioprocesses.

15 December 2024
Verified
Preprint
Open access
PDF file
IHInés Harguindeguy
Inés Harguindeguy
MAMatías Assandri
Matías Assandri
JGJuan Gorgojo
Juan Gorgojo
YHYanina Hiriart
Yanina Hiriart
VAVanina Alarcón
Vanina Alarcón
GOGaston Ortiz
Gaston Ortiz
Bacterial vaccines using recombinant antigens displayed on the bacterial surface represent a major advancement in vaccine development. This approach leverages bacteria’s natural ability to induce immune responses while improving vaccine targeting and efficacy. Existing platforms, such as live bacterial vaccines, inactivated bacterial vaccines, and bacterial-like particles (BLPs), face challenges like genetic modifications, antigen dilution, and degradation. To address these limitations, a novel system called Coated Bacterial Vaccine (CBV) is proposed, combining the benefits of inactivated bacterial vaccines and BLPs technology. The recombinant antigen is fused to the carboxy-terminal cell wall-binding domain of the Lactobacillus SlpA protein (dSLPA) and anchored in vitro on chemically inactivated Gram-positive bacteria. To validate this system, CBVs were created using inactivated B. subtilis 15245 and the TTFC antigen, a fragment of tetanus toxin (TeTx) fused with dSLPA. CBVs were used to immunize BALB/c mice, and anti-TTFC IgG antibodies were measured. Mice were then challenged with TeTx to assess the protective effects of CBVs. Results showed a 100% survival rate in vaccinated mice after TeTx challenge, driven by a robust anti-TTFC IgG response, particularly elevated IgG1 levels. Additionally, macrophage stimulation assays showed increased mRNA levels for IL-1β, IL-6, and IL-10, along with significant IL-6 secretion. These findings demonstrate that CBVs based on B. subtilis can provide effective immune protection through a Th2-polarized response, highlighting the potential of CBVs as a versatile tool for developing new-generation vaccines.